Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/15/2018 10:52:35 PM - Followers: 71 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#3176   This PR/IR strategy really stinks IMO. It would have CUIN2 01/15/18 10:52:35 PM
#3175   lol. anyone manage to get hold of our glorious ceo MIKE22CA 01/11/18 10:48:10 AM
#3174   Good volume today suerte88 01/11/18 10:27:20 AM
#3173   Do not feel bad. Check out what CUIN2 01/09/18 08:24:51 PM
#3172   It's really sad to see you've become a none65 01/09/18 08:23:34 PM
#3170   Does anyone here speak with any regularity with citoyen 01/03/18 03:55:39 PM
#3169   Not sure. CUIN2 01/03/18 12:58:07 PM
#3168   Should we be expecting a news release this month? bigone 01/03/18 12:57:35 PM
#3167   No idea. Very little communication from management CUIN2 12/31/17 05:27:34 PM
#3166   Does somebody know when they are running out suerte88 12/30/17 04:21:19 AM
#3165   Been keeping up with everyone's thoughts here, agree Jason_Bourne 12/29/17 11:20:36 PM
#3164   Good luck. CUIN2 12/29/17 11:24:32 AM
#3163   Feels like some kind of financing is coming. Gene_Simmons 12/29/17 02:53:55 AM
#3162   Still here, still watching. As soon as Jason_Bourne 12/28/17 09:15:58 PM
#3161   When PMH have found them and all have Gene_Simmons 12/23/17 01:56:59 PM
#3160   When is an update coming from the company CUIN2 12/23/17 01:16:11 PM
#3159   I don't understand the steady slide lately. stainedone 12/11/17 10:47:19 AM
#3158   Thanks for your input. I see your points. bigone 11/28/17 12:30:11 PM
#3157   Please note, that the following is just my opinion: suerte88 11/28/17 10:33:13 AM
#3156   More good news and the share price drops bigone 11/27/17 08:30:17 PM
#3155   Theralase Therapeutic Laser Technology Enhances Cancer Destruction suerte88 11/27/17 07:21:21 AM
#3154   Into da ground suerte88 11/24/17 10:47:51 AM
#3153   So quit possibly we tread water for 6 bigone 11/24/17 07:32:42 AM
#3152   Not sure, but as far as we know CUIN2 11/24/17 01:11:04 AM
#3151   Anyone have a feeling for where the company bigone 11/23/17 05:54:33 PM
#3150   Theralase Anti-Cancer Vaccine Validated in Colorectal Cancer suerte88 11/22/17 09:17:38 AM
#3149   Do we close in red today? Loool unbelievable suerte88 11/20/17 10:35:45 AM
#3148 heavymetal 11/20/17 07:45:27 AM
#3147   Wow! Theralase is really churning out some impressive Anesthesia 2007 11/20/17 07:35:31 AM
#3146   Wow 1.7M on the ask at .235 —- MasterSalix 11/14/17 12:50:36 PM
#3145   Easy come easy go suerte88 11/14/17 10:06:24 AM
#3144   if the new compounds do no harm to heavymetal 11/13/17 01:37:13 PM
#3143   Trading resumed suerte88 11/13/17 01:36:20 PM
#3142   CUIN... fwiw.... interesting news today, though will require citoyen 11/13/17 01:27:02 PM
#3141   shorts, what to do now? heavymetal 11/13/17 01:23:31 PM
#3140   We heard of the newer and far more hubwolf1 11/13/17 01:20:30 PM
#3139   " a new Phase Ib clinical study.” heavymetal 11/13/17 01:12:32 PM
#3138   Wait for more attention and restart trading with suerte88 11/13/17 01:11:47 PM
#3137   Now we are up 50% and the stock rawiron1 11/13/17 01:06:31 PM
#3136   Trading halted? firefight 11/13/17 01:05:39 PM
#3135   I? cut this from today’s PR “I? look forward CUIN2 11/13/17 12:51:23 PM
#3134   Donno, but I guess to much volatility. suerte88 11/13/17 12:50:03 PM
#3133   I? wonder why? CUIN2 11/13/17 12:42:18 PM
#3132   Stock is on halt at the moment suerte88 11/13/17 12:41:06 PM
#3131   This is not a bag we are holding. heavymetal 11/13/17 11:21:16 AM
#3130   This news release appears to describe the company bigone 11/13/17 11:03:21 AM
#3129   PDC technology and Dr. McFarland continue to amaze Anesthesia 2007 11/13/17 10:14:12 AM
#3128   Theralase Researcher Discovers Super Potent Anti-Cancer Drugs Toronto, Ontario Anesthesia 2007 11/13/17 10:10:57 AM
#3127   Definitely an overblown response yesterday. We will probably hubwolf1 11/09/17 06:00:15 PM
#3126   Up over 40% since yesterday. But will rawiron1 11/09/17 02:22:11 PM